[1]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 2011, 61(2), 69-90.
[2]
Bray, F.; Ren, J.S.; Masuyer, E.; Ferlay, J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer, 2013, 132, 1133-1145.
[3]
Roos, A.; Ding, Z.; Loftus, J.C.; Tran, N.L. Molecular and microenvironmental determinants of Glioma stem-like cell survival and invasion. Front. Oncol., 2017, 7, 120.
[4]
Ahmed, M.; Moussa, M.; Goldberg, S.N. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem. Phys. Lipids, 2012, 165, 424-437.
[5]
Wang, F.; Ni, H.; Sun, F.; Li, M.; Chen, L. Overexpression of lncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. Biomed. Pharmacother., 2016, 81, 152-159.
[6]
Trabelsi, A.; Ali, A.B.; Yacoub-Abid, L.B.; Stita, W.; Mokni, M.; Korbi, S. Primary invasive micropapillary carcinoma of the colon: Case report and review of the literature. Pathologica, 2008, 100, 428-430.
[7]
Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61, 759-767.
[8]
Lewis, D.F.; Jacobs, M.N.; Dickins, M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov. Today, 2004, 9, 530-537.
[9]
Xu, L.; Qin, Y.; Huang, J.; Qin, J.; Gu, J.; Zhu, H.; Liu, H.; Cai, Y.; Wu, X.; Feng, J. Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer. Anticancer Drugs, 2013, 24, 406-414.
[10]
Bekhit, A.A.; Fahmy, H.T.; Rostom, S.A.; Baraka, A.M. Design and synthesis of some substituted 1H-pyrazolyl- thiazolo[4,5-d]pyrimidines as anti-inflammatory-antimicrobial Agents. ChemInform, 2003, 38, 27-36.
[11]
Venepally, V.; Reddy Jala, R.C. An insight into the biological activities of heterocyclic-fatty acid hybrid molecules. Eur. J. Med. Chem., 2017, 141, 113-137.
[12]
Zhao, Y.; Hui, J.; Zhu, L. Synthesis and bioevaluation of novel arylnaphthalene lignans as anticancer agents. Med. Chem. Res., 2013, 22, 2505-2510.
[13]
Zhao, X.; Tan, Q.; Zhang, Z.; Zhao, Y. 1,3,5-Triazine inhibitors of histone deacetylases: Synthesis and biological activity. Med. Chem. Res., 2014, 23, 5188-5196.
[14]
Yuan, J.W.; Wang, S.F.; Luo, Z.L.; Qiu, H.Y.; Wang, P.F.; Zhang, X.; Yang, Y.A.; Yin, Y.; Zhang, F.; Zhu, H.L. Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents. Bioorg. Med. Chem. Lett., 2014, 24, 2324-2328.
[15]
Reddy, T.S.; Kulhari, H.; Reddy, V.G.; Bansal, V.; Kamal, A.; Shukla, R. Design, synthesis and biological evaluation of 1,3-diphenyl-1H-pyrazole derivatives containing benzimidazole skeleton as potential anticancer and apoptosis inducing agents. Eur. J. Med. Chem., 2015, 101, 790-805.
[16]
Christodoulou, M.S.; Fokialakis, N.; Nam, S.; Jove, R.; Skaltsounis, A.L.; Haroutounian, S.A. Synthesis and biological evaluation of novel pyrazole derivatives as potential antitumor agents. Med. Chem., 2012, 8, 779-788.
[17]
Farag, A.M.; Ali, K.A.; El-Debss, T.M.; Mayhoub, A.S.; Amr, A.G.; Abdel-Hafez, N.A.; Abdulla, M.M. Design, synthesis and structure-activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents. Eur. J. Med. Chem., 2010, 45, 5887-5898.
[18]
Insuasty, B.; Tigreros, A.; Orozco, F.; Quiroga, J.; Abonía, R.; Nogueras, M.; Sanchez, A.; Cobo, J. Synthesis of novel pyrazolic analogues of chalcones and their 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)- 1-phenyl-1H- pyrazole derivatives as potential antitumor agents. Bioorg. Med. Chem., 2010, 18, 4965-4974.
[19]
Farag, A.M.; Mayhoub, A.S.; Eldebss, T.M.; Amr, A.G.; Ali, K.A.; Abdel-Hafez, N.A.; Abdulla, M.M. Synthesis and structure-activity relationship studies of pyrazole-based heterocycles as antitumor agents. Arch. Pharm., 2010, 343, 384-396.
[20]
Knorr, L. Action of ethyl acetoacetate on hydrazine-quinizine derivatives. Chem. Ber., 1883, 17, 546-552.
[21]
Keter, F.K.; Darkwa, J. Perspective: The potential of pyrazole-based compounds in medicine. Biol. Met., 2012, 25, 9-21.
[22]
Küçükgüzel, Ş.G.; Şenkardeş, S. Recent advances in bioactive pyrazoles. Eur. J. Med. Chem., 2015, 97, 786-815.
[23]
Li, J.F.; Jin, H.J.; Zhou, H.Y.; Rothfussa, J.; Tu, Z.D. Synthesis and biological evaluation of pyrazole group-containing analogues for PDE10A. MedChemComm, 2013, 4, 443-449.
[24]
Park, H.J.; Lee, K.; Park, S.J.; Ahn, B.; Lee, J.C.; Cho, H.; Lee, K.I. Identification of antitumor activity of pyrazole oxime ethers. Bioorg. Med. Chem. Lett., 2005, 15, 3307-3312.
[25]
Zheng, L.W.; Li, Y.; Ge, D.; Zhao, B.X.; Liu, Y.R.; Lv, H.S.; Ding, J.; Miao, J.Y. Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells. Bioorg. Med. Chem. Lett., 2010, 20, 4766-4770.
[26]
Dai, H.; Ge, S.; Li, G.; Chen, J.; Shi, Y.; Ye, L.; Ling, Y. Synthesis and bioactivities of novel pyrazole oxime derivatives containing a 1,2,3-thiadiazole moiety. Bioorg. Med. Chem. Lett., 2016, 26, 4504-4507.
[27]
Dai, H.; Ge, S.; Guo, J.; Chen, S.; Huang, M.; Yang, J.; Sun, S.; Ling, Y.; Shi, Y. Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage. Eur. J. Med. Chem., 2018, 143, 1066-1076.
[28]
Keter, F.K.; Kanyanda, S.; Lyantagaye, S.S.; Darkwa, J.; Rees, D.J.; Meyer, M. Evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents. Cancer Chemother. Pharmacol., 2008, 63, 127-138.
[29]
Gomha, S.M.; Edrees, M.M.; Altalbawy, F.M. Synthesis and characterization of some new bis- pyrazolyl-thiazoles incorporating the thiophene moiety as potent anti-tumor agents. Int. J. Mol. Sci., 2016, 17E1499
[30]
Zhao, M.Y.; Yin, Y.; Yu, X.W.; Sangani, C.B.; Wang, S.F.; Lu, A.M.; Yang, L.F.; Lv, P.C.; Jiang, M.G.; Zhu, H.L. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V600E) inhibitors. Bioorg. Med. Chem., 2015, 23, 46-54.
[31]
Zou, Z.; Chang, H.; Li, H.; Wang, S. Induction of reactive oxygen species: An emerging approach for cancer therapy. Apoptosis, 2017, 22, 1321-1335.
[32]
Lu, Y.; Zhang, R.; Liu, S.; Zhao, Y.; Gao, J. ZT-25, a new vacuolar H(+)-ATPase inhibitor, induces apoptosis and protective autophagy through ROS generation in HepG2 cells. Eur. J. Pharmacol., 2016, 771, 130-138.
[33]
Zafarullah, M.; Li, W.Q.; Sylvester, J.; Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci., 2003, 60, 6-20.
[34]
Sha, M.; Ye, J.; Zhang, L.X.; Luan, Z.Y.; Chen, Y. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-κB signaling pathway. Pharmacology, 2014, 93, 39-46.
[35]
Wang, F.; Ma, H.X.; Liu, Z.G.; Huang, W.; Xu, X.J. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice. Biomed. Pharmacother., 2017, 92, 672-680.
[36]
Harada, T.; Harada, K.; Ueyama, Y. The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma. Int. J. Oncol., 2012, 41, 565-572.
[37]
Dai, H.; Li, G.; Chen, J.; Shi, Y.; Ge, S.; Fan, C.; He, H. Synthesis and biological activities of novel 1,3,4-thiadiazole-containing pyrazole oxime derivatives. Bioorg. Med. Chem. Lett., 2016, 26, 3818-3821.
[38]
Ling, Y.; Xu, C.; Luo, L.; Cao, J.; Feng, J.; Xue, Y.; Zhu, Q.; Ju, C.; Li, F.; Zhang, Y.; Zhang, Y.; Ling, X. Novel β-Carboline/Hydroxamic acid hybrids targeting both histone deacetylase and DNA display high anticancer activity regulation of the P53 signaling pathway. J. Med. Chem., 2015, 58, 9214-9227.
